BioCopy AG
BioCopy is a biotechnology company focused on revolutionizing cancer drug discovery and development. They utilize a unique AI-powered, end-to-end automated platform to engineer next-generation biotherapeutics with enhanced safety and efficacy. Their platform accelerates the development process, aiming to reduce the time from discovery to clinical evaluation significantly. BioCopy's approach addresses key challenges in the pharmaceutical industry, such as the high cost and failure rates in developing complex biotherapeutics, and the risk of side effects from current treatments. The company is also exploring the application of its platform for immunological and neurological disorders. BioCopy has programs underway in solid and blood cancers and aims to provide drug candidates for clinical evaluation.
BioCopy AG
BioCopy is a biotechnology company focused on revolutionizing cancer drug discovery and development. They utilize a unique AI-powered, end-to-end automated platform to engineer next-generation biotherapeutics with enhanced safety and efficacy. Their platform accelerates the development process, aiming to reduce the time from discovery to clinical evaluation significantly. BioCopy's approach addresses key challenges in the pharmaceutical industry, such as the high cost and failure rates in developing complex biotherapeutics, and the risk of side effects from current treatments. The company is also exploring the application of its platform for immunological and neurological disorders. BioCopy has programs underway in solid and blood cancers and aims to provide drug candidates for clinical evaluation.